Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - diroximeli fumaras - magensaftresistente hartkapseln - diroximeli fumaras 231 mg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, crospovidonum, cellulosum microcristallinum, silica colloidalis anhydrica, triethylis citras, talcum, magnesii stearas, kapselhülle: hypromellosum, e 171, kalii chloridum, carrageenanum, aqua, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - vumerity ist für die behandlung von patienten mit schubförmig remittierend verlaufender multipler sklerose (ms) zur reduzierung der schubhäufigkeit indiziert. - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosi multipla recidivante-remittente - immunosoppressori - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium < 23 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - fingolimodum - capsule rigide - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), aqua, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, e 172 (flavum), pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, carmellosum calcicum, natrii stearylis fumaras corresp. natrium 0.0295 mg, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), alcohol butylicus, aqua purificata, propylenglycolum, ethanolum, alcohol isopropylicus, ammoniae solutio 28 per centum, pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, carmellosum calcicum, natrii stearylis fumaras corresp. natrium 0.0295 mg, kapselhülle: gelatina, e 171, e 102 0.0283 mg, e 110 0.0033 mg, drucktinte: lacca, e 172 (nigrum), alcohol butylicus, aqua purificata, propylenglycolum, ethanolum, alcohol isopropylicus, ammoniae solutio 28 per centum, pro capsula. - multiple sklerose - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori selettivi immunosoppressori - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).